(Q36596089)

15 August 2017

1 reference

title

The prevention of cytomegalovirus disease in renal transplantation (English)

1 reference

15 August 2017

Davis CL

1

1 reference

15 August 2017

publication date

1 September 1990

1 reference

American Journal of Kidney Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

16

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

175-188

1 reference

Cytomegalovirus Infections Following Renal Transplantation

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalic inclusion retinitis in an adult.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Bilateral Retinal Detachment Following Cytomegalovirus Retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Association of renal allograft rejection with virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

An Analysis of Cytomegalovirus Infection and HLA Antigen Matching on the Outcome of Renal Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Effects of Interferon-Alpha on Cytomegalovirus Reactivation Syndromes in Renal-Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

CMV infection, class II antigen expression, and human kidney allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Transmission of cytomegalovirus infection with renal allograft

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The Transplanted Kidney as a Source of Cytomegalovirus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Reinfection of a seropositive allograft recipient by cytomegalovirus from donor kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Acquisition of donor strains of cytomegalovirus by renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Virus infections after transplantation in man. Brief review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Impaired Lymphocyte Transformation Response to Cytomegalovirus and Phytohemagglutinin in Recipients of Renal Transplants: Association with Antithymocyte Globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Association of Herpesvirus Infections with T-Lymphocyte-Subset Alterations, Glomerulopathy, and Opportunistic Infections after Renal Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Complications and monitoring of OKT3 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus infection and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prevalence of cytomegalovirus antibody in subjects between the ages of 6 and 22 years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prevalence of Cytomegalovirus Infection in Homosexual Men

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Epidemiology of cytomegaloviral infection in a heterogeneous population of pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prevalence of CMV antibodies among women of childbearing age in different social environments in southern Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Comparative seroepidemiology of cytomegalovirus infection in the Canadian Arctic and an urban center

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Immunisation trials with live attenuated cytomegalovirus TOWNE 125

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Clinical Trials of Immunization with the Towne 125 Strain of Human Cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus infection and immunity in renal allograft recipients: assessment of the competence of humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Host defenses and immunologic alterations associated with chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cellular Immune Response to Cytomegalovirus Infection After Renal Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cell-mediated immunity to cytomegalovirus in patients receiving immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Effect of interferon alpha on natural killer cell cytotoxicity in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Natural killing of cytomegalovirus-infected targets in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The effect of cyclosporine on immunization with tetanus and keyhole limpet hemocyanin (KLH) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Malignant transformation of hamster embryo fibroblasts following exposure to ultraviolet-irradiated human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus D.N.A. and adenocarcinoma of the colon: Evidence for latent viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Kaposi's sarcoma in recipients of renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Adverse Effects of Cytomegalovirus Vaccination in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus: Pathogenicity, Immunology, and Vaccine Initiatives

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus Disease: Can it be Prevented?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Serologic studies in hairy cell leukemia: high prevalence of Epstein-Barr and cytomegalovirus antibodies and absence of human T-cell lymphotrophic viruses antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Herpes simplex virus and human cytomegalovirus: their role in morphological transformation and genital cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Elevated antibody titers against cytomegalovirus among patients with testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Declining prevalence of Kaposi's sarcoma in homosexual AIDS patients paralleled by fall in cytomegalovirus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Virulence and attenuation of murine cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Double‐blind study of interferon administration in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

1 reference

7 January 2021

A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus-specific antibody responses in renal transplant patients with primary and recurrent CMV infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Chemotherapy of herpesvirus infections: present successes and future hopes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Effect of 9-(2-hydroxy-1-[hydroxymethyl] ethoxymethyl) guanine (DHPG) on cytomegalovirus pneumonitis after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir for severe cytomegalovirus infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir for severe cytomegalovirus infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Human pharmacokinetics and tolerance of oral ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir--have we established clinical value in the treatment of cytomegalovirus infections?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus and the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Antiviral effects of phosphonoformate (PFA, foscarnet sodium)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Foscarnet for cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Foscarnet-induced acute renal failure and effectiveness of haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus Infection in Dialysis Patients and Personnel

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Prevention of transfusion-acquired cytomegalovirus infection in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ganciclovir and immune globulin in cytomegalovirus pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Increased serum beta 2 microglobulin during rejection, cyclosporine-induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Cytomegalovirus in urine specimens has host beta 2 microglobulin bound to the viral envelope: a mechanism of evading the host immune response?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Inhibition of cytomegalovirus replication by smooth-muscle relaxing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

The outcome of 304 primary renal transplants in children (1968-1985)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Use of older patients as cadaveric kidney donors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

Renal transplantation of the infant and young child and the use of pediatric cadaver kidneys for transplantation in pediatric and adult recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2981016-X

7 January 2021

10.1016/S0272-6386(12)81016-X

Identifiers

DOI

1 reference

15 August 2017

1 reference